RADNOR, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

Sales Performance - Q3 sales from continuing operations grew 9%, with constant currency sales growing 10%[2] - TAVR sales reached $1.0 billion, growing 6% year-over-year, with stable pricing globally[3] - TMTT sales surged 73%, driven by the PASCAL and EVOQUE commercial launches[2] - Net sales for the three months ended September 30, 2024, were $1,354.4 million, a 8.9% increase from $1,243.4 million in the same period of 2023[18] - Total sales for Q3 2024 reached $1,354.4 million, an increase of $111.0 million or 8.9% compared to Q3 2023[32] - Transcatheter Aortic Valve Replacement sales were $1,023.3 million, reflecting a GAAP growth rate of 6.5%[32] - Transcatheter Mitral and Tricuspid Therapies experienced a significant growth of 73.4%, with sales of $91.1 million in Q3 2024[32] - Year-to-date sales for 2024 totaled $4,053.7 million, up $310.1 million or 8.3% from the same period in 2023[32] - Sales in the United States for YTD 2024 were $2,393.1 million, representing an 8.6% growth rate[32] - Europe sales for YTD 2024 increased by 11.4% to $978.0 million[32] - Outside of the United States, sales reached $1,660.6 million, reflecting a growth rate of 7.8%[32] Financial Metrics - Adjusted EPS for Q3 was $0.67, slightly above the company's guidance[8] - Gross profit margin for Q3 was 80.7%, up from 79.9% in the same period last year[8] - Operating income for the three months ended September 30, 2024, was $350.6 million, a decrease from $365.9 million in the same period of 2023[18] - Net income attributable to Edwards Lifesciences Corporation for the three months ended September 30, 2024, was $3,070.8 million, compared to $384.9 million in the same period of 2023[18] - Basic earnings per share for continuing operations were $0.61 for the three months ended September 30, 2024, compared to $0.55 in the same period of 2023[18] - The effective tax rate for the three months ended September 30, 2024, was 10.1%, down from 13.6% in the same period of 2023[18] - The gross profit margin improved to 80.6% in Q3 2024, up from 79.8% in Q3 2023[26][27] - Operating income for Q3 2024 was $350.6 million, compared to $365.9 million in Q3 2023, indicating a decrease of 4.5%[26][27] - Net income attributable to Edwards Lifesciences Corporation for Q3 2024 was $363.5 million, an increase from $336.1 million in Q3 2023, reflecting a growth of 8.2%[26][27] - Diluted EPS for Q3 2024 was $0.61, compared to $0.55 in Q3 2023, marking an increase of 10.9%[26][27] Expenses and Investments - Research and development expenses rose 4% to $253 million, representing 18.7% of sales[8] - Research and development expenses for the three months ended September 30, 2024, were $253.4 million, up from $242.8 million in the same period of 2023[18] - The company recorded restructuring expenses of $32.9 million in the third quarter of 2024 related to global workforce realignment[23] - Non-GAAP adjustments for litigation expenses in Q3 2024 amounted to $10.8 million, while restructuring expenses were $32.9 million[26] - The company reported a charitable contribution of $30.0 million to the Edwards Lifesciences Foundation in the third quarter of 2024[23] - The company reported a charitable foundation contribution of $30.0 million in Q3 2024, which impacted net income[26] Guidance and Future Outlook - Full year sales growth guidance remains unchanged at 8% to 10%, with Q4 sales expected between $1.33 billion and $1.39 billion[10] - Management expects to provide guidance for sales and sales growth rates on a "constant currency basis" to enhance comparability with historical results[21]

NEWTOWN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, announces the filing of a securities fraud class action on behalf of all purchasers of Edwards Lifesciences Corporation securities (NYSE: EW) between February 6, 2024, and July 24, 2024, inclusive (the “Class Period”). To join this case, go HERE. Investors who purchased Edwards stock during the Class Period may move the U.S. District Court for the Central District of California to appoint them as the lead ...

Core Viewpoint - A class action lawsuit has been filed against Edwards Life Sciences Corporation, alleging violations of federal securities laws related to misleading statements about its Transcatheter Aortic Valve Replacement (TAVR) platform and its financial performance during the class period from February 6, 2024, to July 24, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit represents all individuals and entities that purchased Edwards securities during the specified class period and claims that the company and certain executives made materially false and misleading statements [1][3]. - Investors have until December 13, 2024, to seek appointment as lead plaintiff in the class action lawsuit [1]. Group 2: Company Background - Edwards Life Sciences is an international company focused on researching, developing, and providing products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions [3]. Group 3: Allegations and Financial Impact - The lawsuit alleges that the defendants concealed material adverse facts regarding the TAVR platform, emphasizing their commitment and confidence in its demand in lower-penetrated markets [3]. - On July 24, 2024, Edwards reported disappointing second-quarter financial results and reduced its revenue guidance for the TAVR platform, attributing the poor performance to increased pressure on hospital workflows from the growth of structural heart therapies [4]. - Following the announcement of these results, Edwards's stock price fell by $27.25 per share, representing a nearly 32% decline [4].

RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Edward ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109173&from=3 CLASS PERIO ...

Core Viewpoint - Edwards Lifesciences Corporation is facing a federal securities class action due to allegations of misleading statements regarding its revenue expectations for the fiscal year 2024, particularly concerning its Transcatheter Aortic Valve Replacement (TAVR) platform [3][4]. Group 1: Legal Action and Claims - Faruqi & Faruqi, LLP is investigating potential claims against Edwards and has set a deadline of December 13, 2024, for investors to seek the role of lead plaintiff in the class action [2]. - The complaint alleges that Edwards and its executives violated federal securities laws by failing to disclose material information about the expected revenue growth of TAVR [3]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024 and significantly reduced its revenue guidance for the TAVR platform for the full fiscal year [4]. - Following the announcement, Edwards' stock price plummeted from $86.95 per share to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in one day [5]. Group 3: Company Strategy and Market Dynamics - The company attributed the TAVR revenue setback to increased competition from new structural heart therapies, which strained hospital workflows and led to underutilization of TAVR [4]. - Edwards announced three acquisitions during Q2 2024 aimed at enhancing its treatment alternatives to TAVR, indicating a strategic pivot in response to the challenges faced by the TAVR platform [4].

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024. Edwards is an international company that researches, develops, and provides products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions. For more information, submit a form, ...

LOS ANGELES, Oct. 21, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive ...